Divalproex Sodium
Product Images NDC 50090-5843

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-5843). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
A bar chart comparing the percentage outcomes of Study 1 (YMRS) and Study 2 (MRS) for placebo (PBO) versus divalproex sodium delayed-release tablets (DVPX). Study 1 shows 26% for placebo and 60% for divalproex sodium; Study 2 shows 29% for placebo and 58% for divalproex sodium, with a statistical significance indicated by p < 0.05.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
A line graph titled Figure 2 comparing the percentage reduction in CPS rate against the percentage of patients for Divalproex Sodium delayed-release tablets versus placebo. The vertical axis shows percent reduction from -100% to 100%, with a reference line for no change. The horizontal axis represents patient percentages from 0 to 100. Two curves are shown: one solid line for Divalproex Sodium delayed-release tablets and one dashed line for placebo, illustrating greater improvement with the medication.*
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
A line chart showing the percent reduction in Clinical Feature Score (CFS) rate versus percentage of patients for Divalproex Sodium. Two dosage groups are compared: high dose (solid line) and low dose (dashed line). The vertical axis indicates improvement or worsening in the CFS rate, with zero indicating no change.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates between placebo and Divalproex Sodium delayed-release tablets across two studies. Study 1 shows higher migraine rates for placebo than for Divalproex Sodium. Study 2 also shows higher migraine rates for placebo compared to Divalproex Sodium delayed-release tablets, with noted dose variations.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
Chemical structure of Divalproex Sodium illustrating its molecular composition and arrangement including sodium ions and organic groups.*
FDA Label Image

Label Image (Lbl500905843)

Label Image (Lbl500905843)
Divalproex Sodium 500 mg delayed-release coated tablets carton from A-S Medication Solutions. The label indicates each delayed-release tablet contains divalproex sodium equivalent to 500 mg valproic acid, with a package size of 33 tablets. Storage instructions specify storing at 68 to 77 degrees Fahrenheit.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.